This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Clinical Trials
Poyang
A Phase III, Multicentre, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia.
Overview
This research project is testing an experimental treatment for choroidal neovascularisation secondary to pathologic myopia (mCNV).
This experimental treatment is called Faricimab.
The purpose of this study is to compare the effects of Faricimab versus Ranibizumab in patients with mCNV.
In mCNV, vision loss is caused by the abnormal growth of new, leaky blood vessels at the back of the eye. Faricimab is an antibody that is designed to block the activity of two proteins, vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) which can cause the growth of abnormal blood vessels and the leakage of fluid from them.
Currently available and approved injection-based treatments for mCNV, such as ranibizumab (Lucentis®), only target VEGF.
These medications can improve outcomes in patients with mCNV, but frequent treatments may be required and not everyone responds to treatment.
Studies have shown that Ang-2 may also play an important role in the development of these new, leaky blood vessels at the back of the eye.
Therefore, for some patients with mCNV, blocking both VEGF and Ang-2 may be more effective than blocking VEGF alone, and may also allow treatments to be given less frequently.
Faricimab is approved in Australia for the treatment of patients with other eye diseases such as diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).
In addition, faricimab is used in clinical trials for participants with other eye diseases such as retinal vein occlusion (RVO).
Suitable participants will be invited to attend for a screening visit to determine their eligibility for this trial.
If eligible, enrolled participants would be required to attend planned study visits every 4 weeks for the 12 month duration of the trial.
For further information about this study please contact Cerulea on (03) 86385300 or email info@ceruleaclinicaltrials.org.au
- Principal Investigator
Associate Professor Sanj Wickremasinghe
This research project is testing an experimental treatment for choroidal neovascularisation secondary to pathologic myopia (mCNV).
This experimental treatment is called Faricimab.
The purpose of this study is to compare the effects of Faricimab versus Ranibizumab in patients with mCNV.
In mCNV, vision loss is caused by the abnormal growth of new, leaky blood vessels at the back of the eye. Faricimab is an antibody that is designed to block the activity of two proteins, vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) which can cause the growth of abnormal blood vessels and the leakage of fluid from them.
Currently available and approved injection-based treatments for mCNV, such as ranibizumab (Lucentis®), only target VEGF.
These medications can improve outcomes in patients with mCNV, but frequent treatments may be required and not everyone responds to treatment.
Studies have shown that Ang-2 may also play an important role in the development of these new, leaky blood vessels at the back of the eye.
Therefore, for some patients with mCNV, blocking both VEGF and Ang-2 may be more effective than blocking VEGF alone, and may also allow treatments to be given less frequently.
Faricimab is approved in Australia for the treatment of patients with other eye diseases such as diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).
In addition, faricimab is used in clinical trials for participants with other eye diseases such as retinal vein occlusion (RVO).
Suitable participants will be invited to attend for a screening visit to determine their eligibility for this trial.
If eligible, enrolled participants would be required to attend planned study visits every 4 weeks for the 12 month duration of the trial.
For further information about this study please contact Cerulea on (03) 86385300 or email info@ceruleaclinicaltrials.org.au
- Principal Investigator
Learn more
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.